Pye Seonaid M, Cortes Jorge, Ault Patricia, Hatfield Alan, Kantarjian Hagop, Pilot Richard, Rosti Gianantonio, Apperley Jane F
Department of Haematology, Division of Investigative Science, Imperial College, London, United Kingdom.
Blood. 2008 Jun 15;111(12):5505-8. doi: 10.1182/blood-2007-10-114900. Epub 2008 Mar 5.
Imatinib has now been in use for almost 10 years. Despite this cumulative experience, little is known about its effects on pregnancy; as a result, there are few published data to facilitate the counseling of women who conceive while taking imatinib. The results we now present provide information which may be of use in such circumstances. Of 180 women exposed to imatinib during pregnancy, outcome data are available for 125 (69%). Of those with known outcomes, 50% delivered normal infants and 28% underwent elective terminations, 3 following the identification of abnormalities. There were a total of 12 infants in whom abnormalities were identified, 3 of which had strikingly similar complex malformations that are clearly a cause for concern. It appears that although most pregnancies exposed to imatinib are likely to have a successful outcome, there remains a risk that exposure may result in serious fetal malformations.
伊马替尼已应用近10年。尽管有这些累积的经验，但对于其对妊娠的影响仍知之甚少；因此，几乎没有已发表的数据可用于指导正在服用伊马替尼的孕妇进行咨询。我们现在呈现的结果提供了在这种情况下可能有用的信息。在180名孕期接触伊马替尼的女性中，有125名（69%）可获得结局数据。在已知结局的女性中，50%分娩出正常婴儿，28%进行了选择性引产，其中3例是在发现胎儿异常后进行的。总共识别出12例有异常的婴儿，其中3例有明显相似的复杂畸形，这显然令人担忧。看来，虽然大多数接触伊马替尼的妊娠可能会有成功的结局，但接触仍有导致严重胎儿畸形的风险。
